Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 4/2006

01.04.2006 | Original article

Long-term assessment of striatal dopamine transporters in parkinsonian patients with intrastriatal embryonic mesencephalic grafts

verfasst von: Oliver Pogarell, Walter Koch, Franz J. Gildehaus, Andreas Kupsch, Olle Lindvall, Wolfgang H. Oertel, Klaus Tatsch

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Single-photon emission computed tomography (SPECT) of striatal dopamine transporters (DAT) has been used to demonstrate presynaptic dopaminergic dysfunction and to monitor the progression of Parkinson’s disease. In parkinsonian patients who were implanted with embryonic mesencephalic tissue in the striatum, positron emission tomography (PET) has shown an increase in striatal [18F]dopa uptake as an indicator of graft survival and striatal reinnervation. The aim of this study was to investigate two patients who had undergone bilateral intrastriatal transplantation of human embryonic mesencephalic tissue using SPECT and the 123I-labelled DAT ligand N-(3-iodopropen-2-yl)-2β-carbomethoxy-3β-(4-chlorophenyl) tropane (IPT).

Methods

Two patients were subjected to [123I]IPT SPECT according to a standardised protocol prospectively and repeatedly up to 8 years after transplantation.

Results

From baseline to year 3 after transplantation, mean striatal DAT availability increased by a mean of 61% (93% and 29% in patients 1 and 2, respectively). It then remained relatively stable up to 8 years in patient 2, but increased further by another 77% of baseline values in patient 1. Clinically, both patients experienced a moderate improvement in motor performance but developed moderate (patient 2) to severe (patient 1) off-medication dyskinesias.

Conclusion

Our data indicate that DAT imaging using IPT and SPECT can be used to demonstrate graft survival following dopaminergic tissue implantation. Because SPECT with DAT ligands is widely available in the routine clinical setting, this methodology may be a useful alternative to [18F]dopa PET for repeated scanning of grafted parkinsonian patients. The relevance of the long-term increase in DAT binding for the development of off-medication dyskinesias remains to be elucidated further.
Literatur
1.
Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71–6PubMedCrossRef
2.
Oertel WH, Quinn, N. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, eds. Neurological disorders: course and treatment. San Diego, CA: Academic Press; 1996; p. 715–72
3.
Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med 1998;339:1130–43PubMedCrossRef
4.
Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998;339:1044–53PubMedCrossRef
5.
Annett L. Functional studies of neural grafts in parkinsonian primates. In: Dunnett SB, Björklund A, eds. Functional neural transplantation. New York: Raven Press; 1994; p. 71–102
6.
Brundin P, Duan WM, Sauer H. Functional effects of mesencephalic dopamine neurons and adrenal chromaffin cells grafted to the rodent striatum. In: Dunnett SB, Björklund A, eds. Functional neural transplantation. New York: Raven Press; 1994; p. 9–46
7.
Lindvall O, Hagell P. Clinical observations after neural transplantation in Parkinson’s disease. Prog Brain Res 2000;127:299–320PubMedCrossRef
8.
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001;344:710–9PubMedCrossRef
9.
Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403–14PubMedCrossRef
10.
Polgar S, Morris ME, Reilly S, Bilney B, Sanberg PR. Reconstructive neurosurgery for Parkinson’s disease: a systematic review and preliminary meta-analysis. Brain Res Bull 2003;60:1–24PubMedCrossRef
11.
Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H, et al. Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci 2002;5:627–8PubMed
12.
Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson’s disease with PET. J Neural Transm Suppl 2000;60:125–37PubMed
13.
Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brain 2000;123(Pt 7):1380–90PubMedCrossRef
14.
Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 1995;332:1118–24PubMedCrossRef
15.
Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson’s disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001;22:721–5PubMedCrossRef
16.
Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, et al. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415–21PubMed
17.
Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24PubMed
18.
Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993;90:11965–9PubMedCrossRef
19.
Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson’s disease follows a single exponential rather than linear decline. J Nucl Med 2004;45:1694–7PubMed
20.
Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 2001;57:2089–94PubMed
21.
Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T. Measuring the rate of progression of Parkinson’s disease over a 5-year period with beta-CIT SPECT. Mov Disord 2003;18:1266–72PubMedCrossRef
22.
Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson’s disease progression. J Neurol 2004;251 Suppl 7:vII9–13PubMedCrossRef
23.
Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson’s disease. J Neural Transm 2001;108:1011–9PubMedCrossRef
24.
Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, et al. Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001;16:608–15PubMedCrossRef
25.
Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314–9PubMedCrossRef
26.
Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989;46:615–31PubMed
27.
Rehncrona S. A critical review of the current status and possible developments in brain transplantation. Adv Tech Stand Neurosurg 1997;23:3–46PubMed
28.
Fahn S, Elton RL. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson’s disease. Florham Park, NJ: Macmillan Health Care Information; 1987; p. 153–64
29.
Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2–13PubMedCrossRef
30.
Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Mov Disord 1998;13:383–93PubMedCrossRef
31.
Sperfeld AD, Collatz MB, Baier H, Palmbach M, Storch A, Schwarz J, et al. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 1999;46:708–15PubMedCrossRef
32.
Linke R, Gostomzyk J, Hahn K, Tatsch K. [123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 2000;27:1809–12PubMedCrossRef
33.
Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage 2004;23:1–16PubMedCrossRef
34.
Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995;38:580–8PubMedCrossRef
35.
Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999;56:179–87PubMedCrossRef
36.
Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002;52:628–34PubMedCrossRef
37.
Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat Neurosci 1999;2:1137–40PubMedCrossRef
38.
Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, et al. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts. Ann Neurol 2000;48:689–95PubMedCrossRef
39.
Piccini P. Dyskinesias after transplantation in Parkinson’s disease. Lancet Neurol 2002;1:472PubMedCrossRef
Metadaten
Titel
Long-term assessment of striatal dopamine transporters in parkinsonian patients with intrastriatal embryonic mesencephalic grafts
verfasst von
Oliver Pogarell
Walter Koch
Franz J. Gildehaus
Andreas Kupsch
Olle Lindvall
Wolfgang H. Oertel
Klaus Tatsch
Publikationsdatum
01.04.2006
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-0032-z

Weitere Artikel der Ausgabe 4/2006

European Journal of Nuclear Medicine and Molecular Imaging 4/2006 Zur Ausgabe

Original article

Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom

Original Article

Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors

Original article

Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours

Original article

No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity

Original article

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

Molecular imaging

Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033